Piramal Pharma Solutions (PPS) announced the expansion of its ADC capabilities at the manufacturing facility of Piramal Healthcare UK Limited, wholly-owned subsidiary of the Company, at Grangemouth, Scotland.ibbon cutting and commissioning of a multipurpose Antibody-Drug Conjugate (ADC) manufacturing facility that expands capacity by approximately 70-80%. Adrian Gillespie, Chief Executive of Scottish Enterprise, joins senior Piramal management team and site leadership to mark the occasion. The commissioning of the facility represents the culmination of a PS45 million investment to address rapidly growing demand for ADC manufacturing, supported by a PS2.4 million Scottish Enterprise grant.

Piramal Pharma Solutions is a global leader in ADC development and manufacturing, with hundreds of payloads developed and more than a thousand ADC batches manufactured. This expansion further enhances the site's capacity by approximately seventy to eighty%, enabling scale-up of commercial ADC manufacturing batches. The capacity expansion, which has been completed for commercialization within this fiscal year, features two new ADC manufacturing suites specifically designed to complement the existing three.

The PS45 million investment was financed by a combination of Scottish Enterprise government grant, bank loan, customer co-investment, and internal accruals. The primary beneficiaries of the expansion are Piramal's customer and the patients they serve, who are now further supported by the site's enhanced ability to deliver the full life cycle of ADC development and manufacturing. This includes ADCelerate??, the company's branded solution for the rapid early-stage development of ADC drugs.

This integrated offering combines the development of the monoclonal antibody (mAb), linker/payload, conjugation, and sterile fill/finish into a single integrated program across four global Piramal sites, including Grangemouth. The approach simplifies development and manufacturing, speeding the process by which new compounds can get to the patients who need them. Programs such as ADCelerate, coupled with the highly skilled workforce in Grangemouth, exemplify how Piramal brings the best science to its customers and their patients.

The site expansion also includes a dedicated customer experience center for clients who are visiting the site during development and/or manufacturing activities, along with new Quality Control laboratories, warehousing, office space, and supporting utilities. The building, which utilized modular construction technology to expedite its completion, has been designed to accommodate further expansion. Potential future enhancements may include a new sterile fill/finish suite dedicated to ADCs and two additional large-scale manufacturing suites capable of handling increased batch sizes.